Details for Patent: 11,077,055

Which drugs does patent 11,077,055 protect, and when does it expire?

Patent 11,077,055 protects LANSOPRAZOLE and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 11,077,055

Title:	Orally disintegrating compositions
Abstract:	An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.
Inventor(s):	Moses-Heller; Sheera (Atlit, IL)
Assignee:	Dexcel Pharma Technologies Ltd. (Or-Akiva, IL)
Application Number:	15/238,109
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 11,077,055

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dexcel	LANSOPRAZOLE	lansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	208025-001	Jun 7, 2016		OTC	No	No			Y

International Family Members for US Patent 11,077,055

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3288556
Israel	255048
World Intellectual Property Organization (WIPO)	2016174664